Stage Iii Nsclc clinical trials

Explore recruiting stage iii nsclc clinical trials.

Recruiting stage iii nsclc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Stage Iii Nsclc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

IFCT-2501 IDEATION ctDNA-guIDEd consolidATION immunotherapy after chemoradiotherapy in patients with stage III non-small cell lung cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)

Spain, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Single-Arm Study of Atezolizumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Platinum-Based Concurrent Chemoradiation

Slovenia, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, with Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer

Spain, Norway, Sweden, Poland, France, Germany +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter randomized open label phase II study evaluating the efficacy and the tolerance of adding cemiplimab to Sequential hyPOfractionated chemoRADiotherapy in unfit or elderly patients with unresectable stage III non-small cell lung cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with anaplastic lymphoma kinase positive (ALK+) locally advanced Stage III Non Small Cell Lung Cancer (NSCLC): ALNEO trial-GOIRC-01-2020

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Stage Iii Nsclc trials by city

Stage Iii Nsclc in Toronto Stage Iii Nsclc in Vancouver Stage Iii Nsclc in Montreal Stage Iii Nsclc in Calgary Stage Iii Nsclc in Edmonton Stage Iii Nsclc in Ottawa Stage Iii Nsclc in Winnipeg Stage Iii Nsclc in Quebec City Stage Iii Nsclc in Hamilton Stage Iii Nsclc in Kitchener Stage Iii Nsclc in London Stage Iii Nsclc in Halifax Stage Iii Nsclc in New York Stage Iii Nsclc in Los Angeles Stage Iii Nsclc in Chicago Stage Iii Nsclc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease